CLL patients may soon stop daily pills: new combo aims for Fixed-Duration treatment
NCT ID NCT06958705
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding venetoclax (a targeted drug) to ongoing BTK inhibitor therapy can help people with chronic lymphocytic leukemia (CLL) achieve deep remission and then stop all treatment. About 79 adults who have been on a BTK inhibitor for at least 6 months and are still responding will receive venetoclax for 12 cycles. After that, both drugs are stopped and patients are monitored. The goal is to see if this fixed-duration approach can maintain remission without lifelong medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax (a targeted drug) added to a BTK inhibitor (ibrutinib, zanubrutinib, orelabrutinib, or acalabrutinib)
What this could lead to
If successful, this approach could allow CLL patients to stop all medication after a fixed treatment period, instead of taking drugs indefinitely.
What could go wrong
This is a small, early-phase (phase 2) study with only 79 participants. It may not work for everyone, and side effects from combining two powerful drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact